Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on equity-74.5%-24.8pp-64.7%-70.8%-61.3%-49.7%
Return on assets-60.4%-15.7pp-53.9%+13.2pp-61.2%-53.8%-44.7%
Return on invested capital-94.5%+5.1pp-116.4%-103.7%-98.1%-99.6%
Liquidity
Current ratio8.1×+0.7×7.8×-0.9×5.2×-5.3×5.4×-9.5×7.4×-9.7×
Quick ratio8.1×+0.7×7.8×-0.9×5.2×-5.3×5.4×-9.5×7.4×-9.7×
Cash ratio1.1×-0.6×3.4×+0.5×-2.4×1.3×-4.3×1.7×-8.5×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Interest coverage-144.7×+1,161×-346.6×+658×-2,350.5×-1,592×-1,751.3×-1,193×-1,306.1×-877×
Per Share
Book value per share$3.24-37.6%$5.25-24.5%$3.50-50.1%$4.27-44.8%$5.18-65.9%
Valuation
Market capitalization$498.52M+276%$560.3M+247%$259.47M+23.0%$137.87M-57.4%$83.32M-85.9%
Enterprise value$475.49M+475%$440.81M+497%$230.33M+97.9%$90.35M-55.5%$33.39M-91.2%
Price / book2.5×+2.0×2.4×+1.8×1.7×+1.0×0.7×-0.2×0.4×-1.3×
Earnings yield-31.4%+78.2pp-28.8%+50.2pp-62%-9.6pp-115.1%-86.8pp-174.5%-162pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Kyverna Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Kyverna Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.